Reclast

Reclast is a brand name of zoledronic acid, approved by the FDA in the following formulation(s):

RECLAST (zoledronic acid - injectable; iv (infusion))

• 
  Manufacturer: NOVARTIS
  
  Approval date: April 16, 2007
  
  Strength(s): EQ 5MG BASE/100ML ^[RLD]

Has a generic version of Reclast been approved?

No. There is currently no therapeutically equivalent version of Reclast available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Reclast. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substituted alkanediphosphonic acids and pharmaceutical use
  Patent 4,939,130
  Issued: July 3, 1990
  Inventor(s): Jaeggi; Knut A. & Widler; Leo
  Assignee(s): Ciba-Geigy Corporation
  Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.1 is a functionally modified phosphono group and X.sub.2 is a free or functionally modified phosphono group, X.sub.1 and, if appropriate X.sub.2, into the free phosphono group.
  
  Patent expiration dates:
  
  
  • September 2, 2012
    
    ✓ 
    Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical products comprising bisphosphonates
  Patent 7,932,241
  Issued: April 26, 2011
  Inventor(s): Glausch; Alexandra & Löffler; Rolf & Sigg; Juergen
  Assignee(s): Novartis AG
  A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
  
  Patent expiration dates:
  
  
  • February 5, 2028
    
    ✓ 
    Drug product
  
  
  
  • August 5, 2028
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method of administering bisphosphonates
  Patent 8,052,987
  Issued: November 8, 2011
  Inventor(s): Horowitz; Zebulun D. & Richardson; Peter C. & Trechsel; Ulrich
  Assignee(s): Novartis Pharmaceuticals Corporation
  The invention relates to bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, and to methods of treatment using bisphosphonates. These bisphosphonates are used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.
  
  Patent expiration dates:
  
  
  • March 19, 2024
    
    ✓ 
    Patent use: TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 17, 2010 - TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  
  
  • October 16, 2010 - PEDIATRIC EXCLUSIVITY
  
  
  • February 17, 2011 - PEDIATRIC EXCLUSIVITY
  
  
  • December 19, 2011 - TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
  
  
  • March 15, 2012 - TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
  
  
  • May 29, 2012 - PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  
  

See also...

• Reclast Consumer Information (Drugs.com)
• Reclast Consumer Information (Wolters Kluwer)
• Reclast Consumer Information (Cerner Multum)
• Reclast Advanced Consumer Information (Micromedex)
• Zoledronic Acid Consumer Information (Wolters Kluwer)
• Zoledronic acid Consumer Information (Cerner Multum)
• Zoledronic acid Intravenous Advanced Consumer Information (Micromedex)
• Zoledronic Acid AHFS DI Monographs (ASHP)